Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Australian medicinal cannabis revenue is tipped to double this year amid growing confidence in the emerging sector. And WA is poised to maintain a significant hold of the market share.
While the State is recognised globally for its optimal growing conditions, local cultivators, manufacturers and researchers have also benefited from limited COVID-19 interference in their operations.
***
Dr Washer said the trials were critical for the future success of the business.
“Mainstream medicine is where you want to be, and you need the right data to achieve this,” he said. “This is what makes a company attractive to big pharmaceuticals.”
Synthetic medicinal cannabis is more expensive to produce but is more accurate in eradicating THC, the compound in recreational marijuana that produces the “high” sensation.
Dr Washer said having cannabis products that were 100 per cent THC-free would be important to receive US Food and Drug Administration approval.
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2021-04-08-at-7.44.13-am.png10961566Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-04-07 21:45:032023-03-13 21:16:32Australian medicinal cannabis revenue tipped to reach $200 million in 2021
Papulopustular rosacea is a highly visible and distressing chronic inflammatory skin disease characterised by intensely inflamed skin and acne-like breakouts across the face – and new therapies are in demand.
Botanix has today announced that we have received ethics approval for our BTX 1702 Phase 1b clinical study for the treatment of papulopustular rosacea, together with an expansion of the study design.
BTX 1702 is a new formulation which leverages our proprietary drug delivery system Permetrex™ with synthetic cannabidiol.
Our BTX 1702 product offers a novel potential treatment for papulopustular rosacea, with a unique mechanism of action, which could target several aspects in the pathogenesis of the disease.
We are very excited to be initiating this clinical study with leading investigators in Australia and New Zealand.
The Australian Government has published the Final Progress Report for Australia’s First National Antimicrobial Resistance Strategy 2015–2019 detailing its efforts to limit the incidence of antimicrobial resistance (AMR) in Australia.
The report highlights activities implemented between 2017 and 2019 in the human and animal health, food production and the environment.
Looking ahead, the Australian Government last year announced more than $22.5 million over four years in the 2020–21 Budget to implement an effective strategic framework for addressing AMR.
Botanix supports all efforts by the government and industry to address this pressing global health emergency. We are proud to be doing our part in the development of our BTX 1801 antimicrobial platform program too – most recently, we published world-first human data showing that our synthetic CBD-based ointment/gel formula can effectively eradicate Staphylococcus Aureus.
https://botanixpharma.com/wp-content/uploads/BOT_Progress-Report_FB.png788940Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-03-25 00:38:102023-03-13 21:16:44Progress Report for Australia’s First National AMR Strategy
Botanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, presented at the ASX Small and Mid-Cap Conference today.
View the presentation here:
https://botanixpharma.com/wp-content/uploads/FB_BOT_NEW.png788940Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-03-16 00:00:512023-03-13 21:16:44Presentation: ASX Small and Mid-Cap Conference
Article extract | “Novartis’ acquisition represents a double-down on an antibiotics field facing an existential crisis from resistant “super bugs” that have sent most major drugmakers running for the hills — including Novartis, which dumped its antibiotic R&D program in 2018. But adding ever-greater volume to their generic antibiotics portfolio could offer Novartis some bottom-line value in the dwindling space.”
Click through to read the full article on Endpoints News.
https://botanixpharma.com/wp-content/uploads/AdobeStock_226352071-scaled.jpeg17072560Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-02-12 21:24:042023-03-13 21:16:44Novartis’ Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes
Click through to read the full article on Stockhead.
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2021-02-23-at-11.49.33-am.png11641518Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-02-05 12:49:172023-03-13 21:16:44ScoPo’s powerplays: Jazz Pharma’s $9.4b deal highlights pot plays
Australian medicinal cannabis revenue tipped to reach $200 million in 2021
/in Featured, Latest News, News /by Haley ChartresAustralian medicinal cannabis revenue is tipped to double this year amid growing confidence in the emerging sector. And WA is poised to maintain a significant hold of the market share.
While the State is recognised globally for its optimal growing conditions, local cultivators, manufacturers and researchers have also benefited from limited COVID-19 interference in their operations.
***
Dr Washer said the trials were critical for the future success of the business.
“Mainstream medicine is where you want to be, and you need the right data to achieve this,” he said. “This is what makes a company attractive to big pharmaceuticals.”
Synthetic medicinal cannabis is more expensive to produce but is more accurate in eradicating THC, the compound in recreational marijuana that produces the “high” sensation.
Dr Washer said having cannabis products that were 100 per cent THC-free would be important to receive US Food and Drug Administration approval.
***
Click through to read the full article on The West Australian.
Rosacea Study Approval
/in ASX Releases, Featured, Latest News /by Haley ChartresPapulopustular rosacea is a highly visible and distressing chronic inflammatory skin disease characterised by intensely inflamed skin and acne-like breakouts across the face – and new therapies are in demand.
Botanix has today announced that we have received ethics approval for our BTX 1702 Phase 1b clinical study for the treatment of papulopustular rosacea, together with an expansion of the study design.
BTX 1702 is a new formulation which leverages our proprietary drug delivery system Permetrex™ with synthetic cannabidiol.
Our BTX 1702 product offers a novel potential treatment for papulopustular rosacea, with a unique mechanism of action, which could target several aspects in the pathogenesis of the disease.
We are very excited to be initiating this clinical study with leading investigators in Australia and New Zealand.
Read today’s ASX release here.
[The person featured in the above image is not an affiliate or actual patient of Botanix Pharmaceuticals Ltd.]
Progress Report for Australia’s First National AMR Strategy
/in ASX Releases, Featured, Latest News /by Haley ChartresThe Australian Government has published the Final Progress Report for Australia’s First National Antimicrobial Resistance Strategy 2015–2019 detailing its efforts to limit the incidence of antimicrobial resistance (AMR) in Australia.
The report highlights activities implemented between 2017 and 2019 in the human and animal health, food production and the environment.
Looking ahead, the Australian Government last year announced more than $22.5 million over four years in the 2020–21 Budget to implement an effective strategic framework for addressing AMR.
Botanix supports all efforts by the government and industry to address this pressing global health emergency. We are proud to be doing our part in the development of our BTX 1801 antimicrobial platform program too – most recently, we published world-first human data showing that our synthetic CBD-based ointment/gel formula can effectively eradicate Staphylococcus Aureus.
Download Australian Government’s Progress Report here.
Presentation: ASX Small and Mid-Cap Conference
/in Featured, Latest News, News /by Haley ChartresBotanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, presented at the ASX Small and Mid-Cap Conference today.
View the presentation here:
Novartis’ Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes
/in Featured, Latest News, News /by Haley ChartresArticle extract | “Novartis’ acquisition represents a double-down on an antibiotics field facing an existential crisis from resistant “super bugs” that have sent most major drugmakers running for the hills — including Novartis, which dumped its antibiotic R&D program in 2018. But adding ever-greater volume to their generic antibiotics portfolio could offer Novartis some bottom-line value in the dwindling space.”
Click through to read the full article on Endpoints News.
ScoPo’s powerplays: Jazz Pharma’s $9.4b deal highlights pot plays
/in Featured, Latest News, News /by Haley Chartres‘A huge acquisition in the international medical cannabis sector is set to give tailwinds to several ASX-listed marijuana companies, Scott Power says.
Ireland-based Jazz Pharmaceuticals (NASDAQ:JAZZ) this week agreed to buy cannabinoid drugmaker GW Pharmaceuticals (NASDAQ:GWPH) for $US7.2 billion ($9.4 billion) – a 50 per cent premium to GW’s closing price on Tuesday.’
Click through to read the full article on Stockhead.